Xinlitai Erlotinib Hydrochloride Tablets Enters the Administrative Approval Stage

Recently, Xinlitai has entered the administrative examination and approval stage with the imitation of erlotinib hydrochloride tablets submitted for production in category 4, and is expected to be approved and deemed to have been reviewed

Erlotinib is the first-generation EGFR inhibitor developed by Roche.

Roche's global sales of erlotinib peaked at 1.

According to data from Meinenet, in 2020, the total sales of erlotinib in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and terminal erlotinib in Chinese urban physical pharmacies will exceed 300 million yuan

Terminal erlotinib sales in physical pharmacies in cities in China (unit: ten thousand yuan)

Source: Mi Nei.

Currently there are five generic companies approved erlotinib hydrochloride tablets, including Shanghai, a promise, Stockhausen medicine, Terry Pharmaceutical, Nanjing force Bovee, Cologne medicine and so on

Source: Mi Nei Net database, NMPA